Login
Companies $GPCR
$18.56 -$0.01 (0.05%) After hours
Structure Therapeutics Inc. logo

Structure Therapeutics Inc.

structuretx.com

What Do They Do?

Develops oral small-molecule medicines for chronic diseases, including obesity and related conditions, using a drug-discovery platform focused on GPCR targets.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $141.2M in FY2025.

Operating income, FY2025
−492% of revenue
▼ −12% (Loss) vs FY2024 (−$158.2M, −439%)
Net income, FY2025
−394% of revenue
▼ −15% (Loss) vs FY2024 (−$122.5M, −340%)
Free cash flow, FY2025
−629% of revenue
▼ −91% (Loss) vs FY2024 (−$117.9M, −327%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −120% (Loss)
vs −$65.7M in Q3 FY2025
  • Nov 9, 2026 Aleniglipron Phase 3 trials began enrolling The two registrational trials are for chronic weight management, with topline data expected in the second half of 2028.

Who Do They Compete With?

Competes with Pfizer, Eli Lilly, Qilu Regor Therapeutics, AstraZeneca/Eccogene, Terns Pharmaceuticals, Jiangsu Hengrui Medicine, Huadong, Sciwind Biosciences, Ascletis, Gilead, Kallyope, MindRank, vTv Therapeutics, Carmot Therapeutics, Roche Group, Kailera Therapeutics, Merck, Novo Nordisk, Sanofi, and Boehringer Ingelheim

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support